Tag
Pharmaceuticals
83 articles
Pharmaceutical companies are navigating a complex landscape of international trade expansion and strategic acquisitions. India is actively pursuing preferential trade agreements with regions like Southern Africa, aiming to diversify markets and enhance access for pharmaceuticals, engineering goods, and other key sectors. Simultaneously, companies like Alivus Life Sciences are bolstering their capabilities through acquisitions, such as IQGenX Pharma, to expand formulation development and CDMO services. These developments, alongside increased investment and facility expansions by firms like Sai Parenterals and Blue Jet Healthcare, suggest a dynamic period of growth and strategic repositioning within the Indian pharmaceutical sector, though challenges like temporary supply disruptions and regulatory adjustments remain.
India and SACU Sign Preferential Trade Agreement Terms
India and Southern African Customs Union signed Terms of Reference for Preferential Trade Agreement negotiations covering eight chapters including goods trade and market access.
Commerce Minister Piyu
India Rwanda First Joint Trade Committee Meeting
India and Rwanda held their first Joint Trade Committee meeting to establish a structured mechanism for reviewing and expanding bilateral commerce.
India is Rwanda's second largest foreign investor an
Lupin President Legal & Compliance Dr. Sofia Mumtaz Demises
Lupin discloses demise of Dr. Sofia Mumtaz, President Legal & Compliance for Canada, ANZ & NEA, on August 17, 2026.
Disclosure made pursuant to SEBI Listing Regulations Regulation 30 and SEBI Master C
PI Industries Q1 Revenue at ₹17,023 Million
PI Industries reported Q1 FY27 unaudited revenue of ₹17,023 million with a 57% gross margin and 22% EBITDA margin.
Domestic Agri business achieved 12% volume growth and 3% revenue growth, with biologi
Innova Captab Board to Restate FY2026 Financials
Board meeting scheduled for 21st August 2026 to approve revision of standalone and consolidated financial statements for Q4 and FY ended 31st March 2026 due to inadvertent errors.
Trading window closu
Alivus Life Sciences acquires 76% stake in IQGenX
Alivus Life Sciences acquires 76% stake in IQGenX Pharma for INR 91.2 million to expand into formulation development.
Acquisition enables integrated end-to-end platform for complex delivery formats in
Alivus Acquires 76% Stake in IQGEN-X for ₹9.12 Crores
Alivus Life Sciences board approved acquiring 76% stake in IQGEN-X Pharma Private Limited for approximately ₹9.12 crores.
The acquisition aims to provide end-to-end solutions in API and CDMO space, ex
Kopran Declares ₹3 Dividend at 67th AGM
Kopran Limited held its 67th AGM on August 18, 2026, approving all agenda items including a final dividend of ₹3 per equity share.
Shareholders re-appointed Varun Somani and appointed Namrata Somani a
Denis Chem Lab 45th AGM Notice and Annual Report 2025-26
Company issued notice for its 45th Annual General Meeting to be held on 25th September 2026 via video conference, including agenda items for dividend approval and director appointments.
Board recommen
Supriya Lifescience Q1 FY27 Revenue Up 31% YoY
Supriya Lifescience reported Q1 FY27 revenue of ₹190 crore, up 31% YoY, though EBITDA declined 8.1% to ₹47 crore due to temporary water scarcity and higher power costs.
Management reaffirmed FY27 guid
Shilpa Medicare US Drug Recall 27,923 Vials
Shilpa Medicare voluntarily recalls 27,923 vials of Pemetrexed Injection in US due to atypical discoloration.
Recall classified as FDA Class II hospital-level recall covering 4 batches of chemotherapy
Mankind Pharma Appoints Anish Bafna Independent Director
Mankind Pharma seeks shareholder approval via postal ballot for appointing Mr. Anish Vanraj Bafna as a Non-Executive Independent Director for a five-year term.
Remote e-voting through NSDL is schedule
Eiko LifeSciences Allots 305,000 Equity Shares
Eiko LifeSciences converted 305,000 warrants into equity shares via preferential allotment, receiving ₹1.26 crore.
Promoter Bhavesh Tanna and V Square Pharmachem were the allottees, increasing their h
Blue Jet Healthcare FY26 Revenue ₹9.47B, PAT Down 19%
Blue Jet Healthcare reported FY26 revenue of ₹9,473 million, down 8% YoY, with net profit declining 19% to ₹2,478 million due to customer inventory destocking.
The company raised ₹8,000 million throug
Natural Capsules Preferential Issue to Promoter Mundra
Natural Capsules Limited calls EGM on September 9, 2026 to seek shareholder approval for a preferential issue of equity shares and warrants.
Proposes to issue 125,000 equity shares at ₹160 each and 50
Blue Jet Healthcare FY26 BRSR Report ESG Disclosures
Blue Jet Healthcare submitted its standalone Business Responsibility and Sustainability Report for FY 2025-26 to BSE and NSE, complying with SEBI Regulation 34(2)(f).
The company reported 90% export c
Sai Parenterals Q1 FY27 Results, Guidance & Strategic Updates
Sai Parenterals reported Q1 FY27 consolidated revenue of ₹182 crore with EBITDA of ₹27 crore at 14.9% margin, maintaining full-year guidance of ₹750 crore revenue and ~17% EBITDA margin.
Board approve
Biocon Receives FDA Approval for Yesintek Autoinjector
Biocon's US subsidiary secured FDA approval for Yesintek® single-dose prefilled autoinjector formats.
The approval covers 45mg/0.5ml and 90mg/ml autoinjectors for treating autoimmune conditions includ
Supreme Court Condones Sun Pharma Tax Delay
Supreme Court heard SLP No.32096/2026 filed by the Deputy Commissioner of Income Tax against Sun Pharmaceutical Industries Ltd.
The Court ordered condonation of delay in filing Income Tax Appeal No.22
Navin Fluorine Q1 FY27 Net Profit Up 108% YoY
Navin Fluorine reported Q1 FY27 consolidated revenue of ₹1,045.1 Cr, up 44% YoY, and PAT of ₹243.31 Cr, up 108% YoY.
Operating EBITDA margin expanded 566 bps YoY to 34.2%, driven by growth across HPP,
Hamps Bio Limited 19th AGM Notice September 2026
Hamps Bio Limited schedules its 19th Annual General Meeting for September 9, 2026, at 12:00 PM at its registered office in Ankleshwar.
AGM agenda includes adopting FY26 financial statements and re-app
Dishman Carbogen Amcis Q1 FY27 Earnings Call Recording
Dishman Carbogen Amcis disclosed audio recording of its Q1 FY2026-27 earnings conference call held on 17th August 2026.
The investor call discussed the company's financial results and performance for
Natural Capsules Subsidiary Director Resigns August 2026
Natural Capsules discloses resignation of Mr. Pramod Kasat as Independent Director of material unlisted subsidiary Natural Biogenex.
Resignation effective August 17, 2026 due to professional commitmen
Resonance Specialties Acquires Kaygee Lab Facility for ₹29.98 Crores
Resonance Specialties Limited seeks shareholder approval via postal ballot for a material related party transaction.
The company proposes to acquire Kaygee Laboratories' Mandideep manufacturing unit o
Indrayani Biotech FY26 Results with Qualified Audit Opinion
Board approved audited standalone and consolidated financial results for Q4 and year ended March 31, 2026, filed under SEBI Regulations 30 and 33.
Auditors issued qualified opinion due to unconfirmed
Medico Remedies Clarifies No Pending Disclosures
Medico Remedies responded to a BSE query confirming no undisclosed material events under SEBI LODR Regulation 30.
The company attributed recent share price and volume movements solely to market condit
Aarti Pharmalabs Q1 FY27 Revenue Up 42% YoY
Aarti Pharmalabs reported Q1 FY27 standalone revenue of ₹535 crore, up 42% YoY, with PAT growth of 49% to ₹71 crore.
The Xanthine derivatives segment achieved its highest-ever quarterly sales, contrib
Entero Healthcare Q1 FY27 Revenue Up 38.2% YoY
Entero Healthcare reported Q1 FY27 consolidated revenue of ₹1,940 crores, up 38.2% YoY, with EBITDA margin reaching 5%.
Organic revenue growth was 17.8% on a reported basis, significantly outpacing th
Gland Pharma Q1 FY27 Revenue Up 20% YoY
Gland Pharma reported Q1 FY27 revenue of INR 18,003 million, a 20% YoY growth, with PAT surging 47% to INR 3,170 million.
The company announced a strategic CDMO agreement with a global pharma firm for
Arrow Greentech Q1 FY27 Revenue Surges 110% QoQ
Arrow Greentech reported Q1 FY27 revenue of ₹878 million, a 110% increase quarter-over-quarter.
EBITDA grew 246% to ₹359 million with margins expanding 1,610 bps to 40.9%.
High-Tech product segment re
Dishman Carbogen Q1FY27 Net Loss ₹579M
• Dishman Carbogen reported a Q1FY27 net loss of ₹578.8M, a 347% YoY decline, on revenue of ₹6,776.4M (-4.3% YoY).
• EBITDA margin collapsed to 8.9% from 19.9% YoY due to CDMO revenue deferment and a
Sun Pharma Wins US Lipitor Antitrust Litigation Appeal
Sun Pharma and subsidiaries secured a favorable US appellate court ruling in the long-running Lipitor antitrust litigation.
The Third Circuit Court affirmed the District Court's summary judgment and d
Government Outlines Essential Medicine Availability Measures
Government implements Free Drugs Service Initiative under NHM to provide free essential medicines in public health facilities, reducing patient out-of-pocket expenditure.
Pharmaceuticals & Medical Dev
PM Janaushadhi Kendras Reach 20,149 with ₹37,200 Crore Savings
20,149 Jan Aushadhi Kendras operational nationwide with 1,833 in Kerala, offering 2,110 medicines and 315 surgical items.
PMBJP generated ₹7,873.85 crore sales over five years, saving citizens approxi
PM Modi Urges Indian Pharma Top-Five Global Entry
PM Modi calls for Indian pharma companies to rank among world's top five during Independence Day address.
Emphasizes building globally recognized Indian brands across pharmaceuticals, consulting, and
Pharma PLI Schemes Disburse ₹7,013 Crore Till March 2026
The PLI Scheme for Pharmaceuticals has disbursed ₹6,659 crore from its ₹15,000 crore outlay since its performance period began in FY 2022-23.
The PLI Scheme for Bulk Drugs has disbursed only ₹87.70 cr
Himachal Pharma MSMEs Receive ₹85.35 Crore Government Support
Government approved ₹37.4 crore grants for two common facility projects in Solan's pharmaceutical cluster under APICF sub-scheme.
Released ₹19.53 crore to Welzo R&D for completed testing laboratory an
Himachal Pradesh Bulk Drug Park ₹1000 Crore Status Update
Department of Pharmaceuticals sanctioned ₹1000 crore for Himachal Pradesh Bulk Drug Park development in Haroli, Una district.
Infrastructure progress includes 60% completion of water systems and 10-12
Odisha Excluded from Central Bulk Drug Park Scheme
The Cabinet approved a scheme in March 2020 to establish three Bulk Drug Parks to reduce manufacturing costs through shared infrastructure.
Thirteen states submitted proposals, with Gujarat, Himachal
Bulk Drugs PLI Scheme: ₹87.7 Cr Incentives Disbursed
48 projects approved under PLI Scheme for Bulk Drugs with ₹6,940 crore outlay, of which ₹87.70 crore incentives disbursed as of March 2026.
Production capacity created for 28 APIs/KSMs/DIs with 18 API
NPPA Regulates Drug Prices Under DPCO 2013 Framework
NPPA fixes ceiling prices for scheduled drugs and caps non-scheduled drug MRP increases at 10% annually under DPCO 2013.
New Uniform Code of Pharmaceuticals Marketing Practices 2024 prohibits gifts to
Government Explains Medicine Price Regulation Framework
The Department of Pharmaceuticals details drug price regulation under DPCO 2013, where NPPA sets ceiling prices for scheduled formulations and retail prices for new drugs.
Out-of-pocket health expendi
PM Janaushadhi Bihar FY26: 410 Kendras, ₹219cr Sales
Pradhan Mantri Bharatiya Janaushadhi Pariyojana opened 410 Kendras in Bihar during FY 2025-26, including 309 in rural areas and 3 in government hospitals.
Sales of ₹219.18 crore generated estimated ci
India Medical Device 2026 Conference Focuses on Global Hub
Department of Pharmaceuticals and FICCI organized the 9th India Medical Device 2026 conference to advance India as a global medical technology manufacturing hub.
Secretary Manoj Joshi emphasized trans
NPPA Regulates 935 Essential Medicine Prices
NPPA regulates drug prices under DPCO 2013, with ceiling prices effective for 935 formulations and retail prices fixed for 3,845 new drugs.
Annual WPI-based price revisions show 0.65% increase for 202
PM Modi Urges Indian Pharma to Enter Global Top Five
PM Modi calls for Indian pharma companies to rank among world's top five during Independence Day speech.
Emphasis on building globally recognized Indian brands across pharmaceuticals, consulting, and
Nectar Lifesciences Corporate Office Relocation to Godrej Eternia
Nectar Lifesciences board approved relocation of corporate office from Plot 110 to Godrej Eternia, Chandigarh.
The change becomes effective from September 15, 2026, as disclosed in regulatory filing.
Gujarat Themis Biosyn Q1 Revenue Up 22% YoY
Gujarat Themis Biosyn reported Q1 FY27 revenue of INR43.8 crores, up 22.1% YoY, with EBITDA margin expanding 867 bps to 47.5%.
Management detailed two major acquisitions: MicroBiopharm Japan for ferme
Anuh Pharma AGM Approves Director Reappointments, Remuneration Revision
Anuh Pharma's 66th AGM approved reappointment of two Non-Executive Non-Independent Directors effective 12th August 2026.
Members approved remuneration revision for both Joint Managing Directors for FY
Nectar Lifesciences Q1 Net Loss of ₹13.14 Crore
Nectar Lifesciences reported a standalone net loss of ₹13.14 crore for Q1 FY27, primarily driven by a ₹251.33 crore loss on investments.
The Board appointed Dr. Gunmala Suri as an Additional Director
Fischer Medical Ventures Two Independent Directors Resign
Fischer Medical Ventures discloses resignation of two independent directors effective August 14, 2026.
Both directors cited personal reasons and professional commitments as resignation causes.
Directo
Gufic Biosciences Q1 FY27 Revenue Rises 15% YoY
Gufic Biosciences reported Q1 FY27 revenue of ₹260.8 crore, a 15% YoY increase, with EBITDA margin expanding to 18.09%.
The company's new Indore injectable facility achieved commercial production, tar
Vaishali Pharma Independent Director Resignation
Mr. Bhaveshkumar Popatlal Upadhyay resigned as Non-Executive Independent Director of Vaishali Pharma Limited effective 14th August 2026.
Resignation was due to personal and unavoidable circumstances,
Gufic Biosciences Philippines Subsidiary Incorporation Approved
Gufic Biosciences board approved incorporation of a Philippines subsidiary for marketing and distribution.
Investment of up to USD 250,000 for 99.99% stake in the new pharmaceutical subsidiary.
Subsid
Gufic Biosciences Q1 FY27 Net Profit Rises 86% YoY
Gufic Biosciences approved unaudited Q1 FY27 standalone net profit of ₹22.46 crore, an 86% increase from Q1 FY26.
Consolidated revenue for the quarter stood at ₹260.82 crore, with a net profit of ₹22.
Orchid Pharma Posts Revised FY26 Results Post-Merger
Orchid Pharma revised its audited standalone and consolidated FY26 financial results to incorporate the NCLT-sanctioned merger with Dhanuka Laboratories, effective from April 1, 2024.
Standalone net p
Innova Captab Q1 FY27 Revenue Up 34% YoY
Innova Captab reported strong Q1 FY27 results with consolidated revenue growth of 34% YoY to INR 470.9 crores and EBITDA growth of 33%.
The CDMO business grew 32% YoY to INR 328.7 crores, while the br
Shivalik Rasayan Q1 FY27 Net Profit Rises 118% YoY
Board approved un-audited standalone and consolidated financial results for Q1 FY27 ended June 30, 2026.
Proposed final dividend of 10% or ₹0.50 per equity share for FY26, subject to AGM approval on S
Gennex Laboratories Q1 FY27 Net Profit at ₹3.96 Crore
• Board approved unaudited standalone and consolidated financial results for Q1 FY27 ended June 30, 2026.
• Standalone net profit stood at ₹395.53 lakhs with revenue from operations of ₹3,467.79 lakhs
Rubicon Research Q1 FY27 Net Profit Up 135% YoY
Rubicon Research reported unaudited Q1 FY27 standalone net profit of ₹824.49 million, a 135% YoY increase from ₹351.52 million.
Consolidated revenue grew 52% YoY to ₹5,343.38 million, with net profit
Parnax Lab Promoter Acquires 361,872 Shares via Gift
Prakash Shah, a promoter of Parnax Lab, acquired 361,872 equity shares (3.15% stake) from fellow promoter Ila Shah via an off-market gift transfer on July 20, 2026.
The transaction is an inter-se tran
Kilitch Drugs Q1 Net Profit Drops 64% YoY
Kilitch Drugs reported standalone Q1 FY2027 net profit of ₹5.05 crore, down 64% from ₹13.99 crore in Q1 FY2026.
Consolidated net profit attributable to owners fell 80% to ₹2.91 crore from ₹14.52 crore
Anlon Healthcare Approves FY26 Results, Major Acquisitions
Board approved audited standalone and consolidated financial statements for FY ended March 31, 2026.
Approved acquisition of 44.94% in Apiqo Organics and 47.41% in Bizotic Lifescience via share swap w
IPC Recognized as WHO SEARN Regional Centre of Excellence
Indian Pharmacopoeia Commission designated as WHO-SEARN Regional Centre of Excellence in Pharmacovigilance and Technical Centre in Quality.
IPC showcased India's regulatory initiatives including pharm
Parliamentary Committee Proposes Major Healthcare Reform Strategy
Committee recommends capping private healthcare costs and expanding Ayushman Bharat coverage to all seniors and children to improve affordability.
Proposes establishing National CKD Registry and expan
Glenmark Life Sciences Promoter Acquires 44,400 Shares
Glenmark Life Sciences discloses promoter group share acquisitions under SEBI Regulation 30.
Promoter group bought 13,200 shares for ₹14.44 lakh on August 5 and 31,200 shares for ₹35.23 lakh on August
Colinz Labs Open Offer for 26% at ₹54/Share
Mandatory open offer by Annjana Dugar, Likhitta Dugar, Antariksh Dugar and PAC Padam Dugar to acquire up to 6,54,966 shares (26% stake) of Colinz Laboratories Ltd at ₹54 per share, aggregating ₹3.53 c
Novartis AG Sells Entire 70.68% Stake
Novartis AG sold its entire 70.68% holding (1.74 crore shares) in Novartis India Limited on July 29, 2026.
The sale was executed off-market pursuant to a purchase agreement dated February 19, 2026.
No
Novartis AG Sells Entire 70.68% Stake in Novartis India
Novartis AG sold its entire 70.68% stake, comprising 1.74 crore equity shares, in Novartis India Limited.
The off-market transaction was valued at approximately ₹1,376.89 crore and executed on July 29
Bliss GVS Open Offer Addendum Adds Mates Visa as PAC
Bliss GVS Pharma received an addendum to an open offer from Anupam Rasayan, designating Mates Visa Consultancy as a person acting in concert (PAC).
The addendum, dated July 17, 2026, discloses Mates V
WaveRise ChrysCapital Novartis India Open Offer Completion
Axis Capital submits post-offer ad for completed open offer by WaveRise Investments and ChrysCapital for 26% stake in Novartis India.
Open offer acquired 64.19 lakh shares at ₹5,524.97 crore total val
Nureca Promoter Group Sells 21.59% Stake
Disclosure under SEBI PIT Regulation 7(2) for an off-market disposal of equity shares by a promoter group member.
Payal Goyal transferred her entire 2,059,928 shares, representing a 21.59% stake, via
Bharat Parenterals Promoter Acquires 1,356 Shares
Bharat Parenterals discloses promoter share acquisition under SEBI PIT Regulation 7(2).
Promoter entity Desai Shares purchased 1,356 equity shares via on-market transactions.
Post-acquisition promoter
Medico Intercontinental Promoter Acquires 1.37 Lakh Shares
Medico Intercontinental promoter MD Samir Shah acquired 1,36,886 equity shares via open market purchases from June 3-24, 2026.
The acquisition was disclosed under SEBI Prohibition of Insider Trading R
Ishita Pharmaceuticals Acquires 223 Shares in Ishita Drugs
Ishita Pharmaceuticals, a related party, acquired 223 shares of Ishita Drugs and Industries Ltd. via open market purchase on June 22, 2026.
The acquisition increases Ishita Pharmaceuticals' total voti
Amanta Healthcare Promoter Purchases 16,200 Shares
Amanta Healthcare Ltd files SEBI PIT Regulation 7(2) disclosure for a promoter's open-market share purchase.
Promoter Jitendrakumar J Patel purchased 16,200 equity shares at ₹24.29 per share on NSE.
T
Zydus Lifesciences Insiders' Buyback Share Acceptance
Zydus Lifesciences discloses insider share transactions under SEBI regulations related to its recent buyback offer.
Promoter Zydus Family Trust accepted 63.5 lakh shares, reducing its holding from 74.
Ishita Pharmaceuticals Acquires 55 Ishita Drugs Shares
Ishita Pharmaceuticals, a related party, acquired 55 equity shares of Ishita Drugs & Industries Ltd. via open market purchase on June 19, 2026.
The acquisition increases Ishita Pharmaceuticals' voting
Novartis India Open Offer Receives Minimal Share Tender
• Axis Capital discloses tender status for Novartis India's 26% open offer by WaveRise and ChrysCapital.
• Zero equity shares tendered in dematerialized form as of June 18, 2026.
• Only 10 physical sh
Colinz Labs 26% Open Offer at ₹54/Share
Annjana, Likhitta, and Antariksh Dugar with Padam Dugar launch a mandatory open offer for 26% of Colinz Laboratories at ₹54 per share.
The offer is triggered by their agreement to acquire 34.56% from
Novartis India Open Offer Receives Zero Shares Tendered
Axis Capital discloses zero equity shares were tendered on June 17, 2026, in the open offer for Novartis India.
The open offer is for acquiring up to 26% of Novartis India's voting share capital from
Novartis India Open Offer Receives Zero Shares
Axis Capital discloses zero equity shares tendered on first day of Novartis India open offer.
No shares were received in both dematerialized and physical form by the offer's escrow and registrar.
The
Parmax Pharma Acquirers Seek Majority Control via SPA
Acquirers led by Dhiren C. Shah and Sunil C. Shah to acquire control of Parmax Pharma through share purchase agreement, preferential allotment, and open offer.
SPA executed at ₹35 per share for 43,210